Tris Pharma Revenue and Competitors

Monmouth Junction, NJ USA

Location

$125M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Tris Pharma's estimated annual revenue is currently $116.5M per year.(i)
  • Tris Pharma's estimated revenue per employee is $281,400
  • Tris Pharma's total funding is $125M.

Employee Data

  • Tris Pharma has 414 Employees.(i)
  • Tris Pharma grew their employee count by 5% last year.

Tris Pharma's People

NameTitleEmail/Phone
1
Head Sales Force Training and Sales Force EffectivenessReveal Email/Phone
2
VP, Engineering & FacilitiesReveal Email/Phone
3
Head ITReveal Email/Phone
4
VP, Research & DevelopmentReveal Email/Phone
5
VP, Quality & ComplianceReveal Email/Phone
6
SVP, Regulatory AffairsReveal Email/Phone
7
VP SalesReveal Email/Phone
8
VP, General CounselReveal Email/Phone
9
Head OperationsReveal Email/Phone
10
Head MSLsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Tris Pharma?

Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies. Our mission is to understand the science of developing drug products with unique attributes, bring to market products that add value to our patients and customers, and provide a benefit to our company, employees and society at large.

keywords:N/A

$125M

Total Funding

414

Number of Employees

$116.5M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tris Pharma News

2022-04-20 - Cough Suppressant Drugs Market Size, Outlook And Forecast ...

Perrigo Company, Vernalis, Tris Pharma, Pfizer, Acella Pharmaceuticals, GlaxoSmithKline. This comprehensive Cough Suppressant Drugs Market report helps in...

2022-04-19 - Methylphenidate Drug Market Size, Scope And Outlook ...

... NEOS Therapeutics, Rhodes Pharmaceuticals, Noven Therapeutics, Ironshore Pharmaceuticals, Lannett Company, Novartis, Teva, Tris Pharma,...

2022-04-17 - Clonidine Market Size, Outlook And Forecast | Physicians ...

... Mylan Pharmaceuticals, Corium International, Mayne Pharma, Advanz Pharma ... Shionogi Pharma, Tris Pharma, Par Pharmaceutical, X Gen Pharmaceuticals,...

2018-10-05 - Tris Pharma Receives $125M Debt Financing from Deerfield

Deerfield provided $125m to refinance existing debt and provide growth capital to Tris Pharma, Inc., a Monmouth Junction, NJ-based fully integrated pharmaceutical company. The company intends to use the funds to expand its branded pharmaceutical portfolio with a particular focus on Attention De ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M4526%N/A
#2
$149M6622%N/A